Phase I trial of dianhydrogalactitol administered iv in a weekly schedule

Charles Vogel, E. F. Winton, M. R. Moore, S. Sohner

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Dianhydrogalactitol was given to 28 patients with a variety of advanced solid tumors on a weekly schedule in iv doses ranging from 2 to 80 mg/m2. No significant toxicity was encountered at doses up to 40 mg/m2/week for 4 weeks. At higher doses mild to moderate nausea and vomiting and hematologic toxicity were noted. Thrombocytopenia was more common than granulocytopenia and frequently resolved more slowly. No adverse drug related effects on liver, renal, coagulation, or cardiac function were seen. Although no patient had significant antitumor response (as strictly defined), objective improvement was noted in two patients, one with hypernephroma and the other with malignant melanoma. For phase II studies, a weekly dose of 70 mg/m2 is recommended for patients with normal hematopoiesis, with reduction by 25% (55 mg/m2) in patients with extensive prior radiation therapy, prior chemotherapy, and/or widespread metastasis to the bone.

Original languageEnglish
Pages (from-to)895-901
Number of pages7
JournalCancer Treatment Reports
Volume60
Issue number7
StatePublished - Dec 1 1976
Externally publishedYes

Fingerprint

Dianhydrogalactitol
Appointments and Schedules
Agranulocytosis
Hematopoiesis
Renal Cell Carcinoma
Thrombocytopenia
Nausea
Vomiting
Melanoma
Radiotherapy
Neoplasm Metastasis
Kidney
Bone and Bones
Drug Therapy
Liver
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Vogel, C., Winton, E. F., Moore, M. R., & Sohner, S. (1976). Phase I trial of dianhydrogalactitol administered iv in a weekly schedule. Cancer Treatment Reports, 60(7), 895-901.

Phase I trial of dianhydrogalactitol administered iv in a weekly schedule. / Vogel, Charles; Winton, E. F.; Moore, M. R.; Sohner, S.

In: Cancer Treatment Reports, Vol. 60, No. 7, 01.12.1976, p. 895-901.

Research output: Contribution to journalArticle

Vogel, C, Winton, EF, Moore, MR & Sohner, S 1976, 'Phase I trial of dianhydrogalactitol administered iv in a weekly schedule', Cancer Treatment Reports, vol. 60, no. 7, pp. 895-901.
Vogel, Charles ; Winton, E. F. ; Moore, M. R. ; Sohner, S. / Phase I trial of dianhydrogalactitol administered iv in a weekly schedule. In: Cancer Treatment Reports. 1976 ; Vol. 60, No. 7. pp. 895-901.
@article{a76b338cf56e408a8772686f33bf472a,
title = "Phase I trial of dianhydrogalactitol administered iv in a weekly schedule",
abstract = "Dianhydrogalactitol was given to 28 patients with a variety of advanced solid tumors on a weekly schedule in iv doses ranging from 2 to 80 mg/m2. No significant toxicity was encountered at doses up to 40 mg/m2/week for 4 weeks. At higher doses mild to moderate nausea and vomiting and hematologic toxicity were noted. Thrombocytopenia was more common than granulocytopenia and frequently resolved more slowly. No adverse drug related effects on liver, renal, coagulation, or cardiac function were seen. Although no patient had significant antitumor response (as strictly defined), objective improvement was noted in two patients, one with hypernephroma and the other with malignant melanoma. For phase II studies, a weekly dose of 70 mg/m2 is recommended for patients with normal hematopoiesis, with reduction by 25{\%} (55 mg/m2) in patients with extensive prior radiation therapy, prior chemotherapy, and/or widespread metastasis to the bone.",
author = "Charles Vogel and Winton, {E. F.} and Moore, {M. R.} and S. Sohner",
year = "1976",
month = "12",
day = "1",
language = "English",
volume = "60",
pages = "895--901",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Phase I trial of dianhydrogalactitol administered iv in a weekly schedule

AU - Vogel, Charles

AU - Winton, E. F.

AU - Moore, M. R.

AU - Sohner, S.

PY - 1976/12/1

Y1 - 1976/12/1

N2 - Dianhydrogalactitol was given to 28 patients with a variety of advanced solid tumors on a weekly schedule in iv doses ranging from 2 to 80 mg/m2. No significant toxicity was encountered at doses up to 40 mg/m2/week for 4 weeks. At higher doses mild to moderate nausea and vomiting and hematologic toxicity were noted. Thrombocytopenia was more common than granulocytopenia and frequently resolved more slowly. No adverse drug related effects on liver, renal, coagulation, or cardiac function were seen. Although no patient had significant antitumor response (as strictly defined), objective improvement was noted in two patients, one with hypernephroma and the other with malignant melanoma. For phase II studies, a weekly dose of 70 mg/m2 is recommended for patients with normal hematopoiesis, with reduction by 25% (55 mg/m2) in patients with extensive prior radiation therapy, prior chemotherapy, and/or widespread metastasis to the bone.

AB - Dianhydrogalactitol was given to 28 patients with a variety of advanced solid tumors on a weekly schedule in iv doses ranging from 2 to 80 mg/m2. No significant toxicity was encountered at doses up to 40 mg/m2/week for 4 weeks. At higher doses mild to moderate nausea and vomiting and hematologic toxicity were noted. Thrombocytopenia was more common than granulocytopenia and frequently resolved more slowly. No adverse drug related effects on liver, renal, coagulation, or cardiac function were seen. Although no patient had significant antitumor response (as strictly defined), objective improvement was noted in two patients, one with hypernephroma and the other with malignant melanoma. For phase II studies, a weekly dose of 70 mg/m2 is recommended for patients with normal hematopoiesis, with reduction by 25% (55 mg/m2) in patients with extensive prior radiation therapy, prior chemotherapy, and/or widespread metastasis to the bone.

UR - http://www.scopus.com/inward/record.url?scp=0017087904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017087904&partnerID=8YFLogxK

M3 - Article

C2 - 795538

AN - SCOPUS:0017087904

VL - 60

SP - 895

EP - 901

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 7

ER -